Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598381 | 1.00 | GRM2 (0.40) | GRM2CYP3A4CYP2D6MAPTCYP2C19 | |
| SCHEMBL20072321 | 1.00 | GRM2 (0.40) | GRM2CYP3A4CYP2D6MAPTCYP2C19 | |
| SCHEMBL28412417 | 1.00 | GRM2 (0.40) | GRM2CYP3A4CYP2D6MAPTCYP2C19 | |
| SCHEMBL4440151 | 1.00 | GRM2 (0.40) | GRM2CYP3A4CYP2D6MAPTCYP2C19 | |
| SCHEMBL29074198 | 1.00 | GRM2 (0.40) | GRM2CYP3A4CYP2D6MAPTCYP2C19 | |
| SCHEMBL598403 | 1.00 | GRM2 (0.40) | GRM2CYP3A4CYP2D6MAPTCYP2C19 | |
| SCHEMBL23477961 | 0.91 | CYP3A4 (0.44) | CYP3A4CYP2D6MAPTCYP2C19CTSD | |
| SCHEMBL22559996 | 0.91 | CYP3A4 (0.44) | CYP3A4CYP2D6MAPTCYP2C19CTSD | |
| SCHEMBL22295471 | 0.82 | CYP26A1 (0.39) | CES2FAAHDAOTSHRNAAA | |
| SCHEMBL22295470 | 0.82 | GRM2 (0.37) | GRM2CES2TSHRSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245009-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060217-A1 | Processes | MME, NAT1, AGTR1 | GRM2 2273/4885CYP3A4 528/4885CYP2D6 326/4885 |
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | GRM2 2361/4885CYP3A4 550/4885CYP2D6 421/4885 |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | GRM2 1541/4885CYP3A4 256/4885CYP2D6 270/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | GRM2 1541/4885CYP3A4 256/4885CYP2D6 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.